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Abstract. In recent years an extensive series of synthetic
combretastatin A-4 (CA-4)-azetidinone (β -lactam) hybrids
were designed and synthesised with a view to improve the
stability, therapeutic efficacy and aqueous solubility of CA-4.
Lead compounds containing a 3,4,5-trimethoxy aromatic ring
at position 1 and a variety of substitution patterns at positions 3
and 4 of the β-lactam ring were screened in three adenocarcinoma-derived colon cancer cell lines (CT-26, Caco-2 and the
CA-4 resistant cell line, HT-29). In both CT-26 and Caco-2
cells all β-lactam analogues analysed displayed potent therapeutic efficacy within the nanomolar range. Substitution of
the ethylene bridge of CA-4 with the β-lactam ring together
with the aforementioned aryl substitutions improved the therapeutic efficacy of CA-4 up to 300‑fold in the combretastatin
refractory HT-29 cells. The lead compound combretazet-3
(CAZ-3); chemical name [4-(3-hydroxy-4-methoxyphenyl)-3(4-hydroxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one]
demonstrated improved chemical stability together with
enhanced therapeutic efficacy as compared with CA-4
whilst maintaining the natural biological properties of CA-4.
Furthermore, CAZ-3 demonstrated significant tumour inhibition in a murine model of colon cancer. Our results suggest
that combretastatin-azetidinone hybrids represent an effective
novel therapy for the treatment of combretastatin resistant
carcinomas.
Introduction
Microtubules are a principle component of the cytoskeleton
and play a key role in numerous biological functions including
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cell division and organelle transport. The pivotal role of tubulin
in both the formation of the mitotic spindle and chromosomal
separation promoted the surge in the development of both
natural and synthetic microtubule targeting agents (MTAs).
One such naturally occurring drug, combretastatin A-4 (CA-4;
Fig. 1) was originally described by Pettit et al (1). The structure
of CA-4 proved readily amenable to chemical manipulation
to improve the stability, solubility and therapeutic index of
this class of MTAs. Over the past two decades a vast array
of synthetic CA-4 analogues were designed and synthesised
with many surpassing the stability, solubility and therapeutic
efficacy of the parent compound (2). The clinical success of
the synthetic prodrug of CA-4, combretastatin-A4 phosphate
(CA-4P) in the treatment of anaplastic thyroid carcinoma
(www.clinicaltrials.gov) (3) has maintained an active interest
in the chemical manipulation of CA-4 with the view to further
enhancing the therapeutic efficacy of this lead compound.
Furthermore, amino acid containing prodrugs of CA-4 are
also undergoing clinical evaluation including AVE8062 (www.
clinicaltrials.gov) (4). Structural modifications of CA-4 can be
divided into three areas, those involving the manipulation of
either ring A, ring B or those involving the substitution of the
double bond (ethylene bridge structure) connecting both rings
(Fig. 1). These A and B substituted aromatic rings fit into the
A and B pockets of the colchicine binding site on tubulin. Data
collated from numerous structural activity relationship (SAR)
studies confirm that a non-planar cis conformation is essential
for the tubulin binding properties of CA-4. Furthermore, the
majority of studies suggest that the 3,4,5-trimethoxy-substituted
aromatic A-ring should be conserved to maintain maximum
anticancer activity. However, contrary to this, a recent study
conducted by Beale et al (5) showed that substitution of the
larger meta-methoxy groups of triazole CA-4 derivatives
with smaller halogen atoms yielded more potent CA-4/CA-1
analogues. Several independent studies have demonstrated
that the therapeutic activity of CA-4 can also be enhanced by
the strategic modification of ring B (6). Apart from strategies
to improve the potency of CA-4 other main areas of research
focused on methods to overcome the solubility issues of CA-4
and also to prevent the undesired conversion into the inactive
trans isomer (Fig. 1). Modification of the phenolic group on
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ring B forming either a phosphate or an amino acid ester was
demonstrated to be an effective method of improving the solubility of CA-4 whilst retaining optimum biological activity.
Double bond isomerisation can be prevented by the strategic
inclusion of various types of heterocyclic rings in place of the
usual ethylene bridge structure of CA-4 (7).
In recent years our group has designed and synthesised
an extensive series of azetidinone (β-lactam) CA-4 analogues
with a view to overcoming double bond isomerisation by
substituting the ethylene bridge structure for a 1,4-diaryl2-azetidinone ring. The rigid β-lactam ring scaffold allows a
similar spatial arrangement between the two aromatic rings as
observed in the non-planar cis-conformation of CA-4 while
permanently preventing the undesired conversion to the inactive trans-configuration (8). Further studies demonstrated that
the inclusion of an aromatic ring at position 3 of the β-lactam
significantly improved the potency of the series. Hence, a
β-lactam substituted at position 3 with a phenolic ring soon
became the core structure for future designs (9). Solubility
issues of the CA-4-azetidinone analogues were addressed by
esterification of the 3'OH group of ring B with phosphates and
amino acids (unpublished data).
However, despite the significant advances made in recent
years in terms of improving the solubility and stability of
CA-4, the lack of therapeutic efficacy as a single agent and the
emergence of resistance to CA-4 has somewhat hindered the
clinical and commercial success of this compound. We recently
reported that CA-432, a lead combretastatin-azetidinone
hybrid was 10‑fold more potent than CA-4 in CA-4 refractory
HT-29 cells, suggesting a possible functional advantage of the
ethylene bridge-azetidinone substitution (10). In this study, we
screened selected combretastatin-azetidinone hybrids (hereafter referred to as combretazets) to further characterise the
structure activity relationship of these compounds in the CA-4
resistant HT-29 cells. The stability and therapeutic potential of
a lead compound combretazet-3 (CAZ-3) as a single agent in
the murine CT-26 colon cancer model was evaluated.
Materials and methods
Compounds. CA-4 and bafilomycin A1 were purchased from
Sigma-Aldrich (Poole, Dorset, UK). 1,4-Diaryl-2-azetidinone
analogues were synthesised as previously described by Carr
et al (8) CAZ-1, CAZ-2 and CAZ-3 (9), CAZ-4 (7), CAZ-5
(11), CAZ-2P, CAZ-3P, CAZ-4P, CAZ-6 and CAZ-7 (unpublished data). All general reagents unless stated otherwise
were purchased from Sigma. Bafilomycin A1 was dissolved
in DMSO. CA-4 and all analogues were prepared as a 10‑mM
stock in ethanol and stored at -20˚C.
Cell culture. CT-26 cells are a chemically (N-nitroso-Nmethylurethane) induced, undifferentiated murine colon
carcinoma fibroblast cell line originating from BALB/c mice.
HT-29 and Caco-2 cells originate from a human adenocarci
noma of the colon and were originally obtained from the
European Collection of Cell Cultures. All cells were grown
in DMEM Glutamax media. CT-26 and HT-29 media were
supplemented with 10% foetal bovine serum (FBS) and
Caco-2 were cultivated with 20% FBS. Both CT-26 and
Caco-2 media were supplemented with 1% non-essential

amino acids (NEAA). All media contained 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were maintained
at 37˚C in 5% CO2 in a humidified incubator. Cell culture
materials were supplied from Gibco, Invitrogen Corp. (Grand
Island, NY, USA). All cells were sub-cultured 3 times/week
by trypsinisation.
Alamar blue cell viability assay. Cell proliferation was analysed
using the Alamar Blue assay (Invitrogen Corp.) according to
the manufacturer's instructions. Cells were seeded at a density
of 5x103 cells/well (CT-26) or 1x104 cells/well (Caco-2, HT-29)
in triplicate in 96‑well plates. After 24 h, cells were then treated
with either medium alone, vehicle [1% ethanol (v/v)] or with
serial dilutions of CA-4 or combretazets. After 72 h, Alamar
Blue [10% (v/v)] was added to each well and plates were incubated for 3-5 h at 37˚C in the dark. Fluorescence was read using
a 96‑well fluorimeter with excitation at 530 nm and emission
at 590 nm. Results were expressed as percentage viability
relative to vehicle control (100%). Dose response curves were
plotted and IC50 values (concentration of drug resulting in 50%
reduction in cell survival) were obtained using the commercial
software package Prism (GraphPad Software, Inc., La Jolla,
CA, USA). Experiments were performed in triplicate on at
least three separate occasions.
Cell cycle detection. After treatment, cells were collected then
centrifuged at 800 x g for 10 min and fixed with 70% ethanol
overnight at -20˚C. The ethanol was removed by centrifugation
at 800 x g for 10 min. The cells were then stained in PBS
containing 0.5 mg/ml RNase A and 0.15 mg/ml propidium
iodide and then incubated for 30 min in the dark at 37˚C. Cell
cycle distribution was analysed by flow cytometry at 488 nm
using the FACSCalibur flow cytometer (Becton-Dickinson,
San Jose, CA). All data were recorded and analysed using the
CellQuest Software (Becton-Dickinson).
Plasma and pH stability studies. Peripheral blood was
collected from healthy donors with informed consent and
was made anonymous prior to use. The plasma was separated
by Ficoll-gradient and diluted (1:9) with PBS pH 7.4 and
warmed to 37˚C. The pH stability study was carried out in
PBS pH 3.0. Test compounds (1.5 mg/ml) were dissolved
in acetonitrile at time t= 0. Plasma solution containing test
compound (250 µl) was added to 2% (w/v) ZnSO4 solution
in acetonitrile: water (1:1) (500 µl). Aliquots were taken at
the specified time intervals, vortexed, centrifuged for 3 min
at 9,500 x g before injection onto an HPLC column (Varian
Pursuit XRs C18 reverse phase 250x4.6 mm chromatography
column) to determine the stability using a Waters 2487
Dual Wavelength Absorbance Detector, a Waters 1525
Binary HPLC Pump, a Waters In-Line Degasser AF and a
Waters 717 plus Autosampler. Samples were detected using
a wavelength of 254 nm. All samples were analysed using
acetonitrile (60%):water (40%) with 0.1% (v/v) trifluoroacetic
acid over 10 min and a flow rate of 1 ml/min to evaluate the
percentage decline in the predetermined peak area for each
compound. The retention times for CA-4 and CAZ-3 were
5.9 and 3.7 min, respectively. The percentage recovery was
calculated using the following formula [(plasma or pH 3.0
peak area/mean aqueous peak area) x 100].
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Figure 1. Structures and nomenclature of combretastatin-A4 and selected combretazets.

Human microsomal stability study. Microsomal stability
was determined using pooled human liver microsomes (The
UK Human Tissue Bank, Leicester, UK). Ethical approval
was obtained from south Cheshire Local Research Ethics
Committee (Chester, UK). Test compound (3 µM) together
with microsome protein (0.5 mg/ml), 1 mM NADPH in 0.1 M
phosphate buffer pH 7.4 was incubated for 0, 5, 15, 30 and
45 min. The negative control did not contain NADPH. The
samples were quenched with methanol and the protein was
precipitated by centrifugation for 20 min at 1,100 x g at 4˚C.
Supernatants were then analysed by LC/MS. The In peak
area ratio (compound peak area/internal standard peak area)
was plotted against time and the slope of the line determined to give the elimination rate constant [K = (-1) (slope)].
The half life (t1/2) and the in vitro intrinsic clearance (CLint
µl/min/mg protein) were calculated by the following equations; t1/2 = 0.693/K; CLint = V (0.693)/t1/2 where V, incubation
volume in µl/mg microsomal protein.
Quantification of AVOs with acridine orange staining using
flow cytometry. Autophagy is characterised by the formation
and promotion of acidic vesicular organelles (AVOs). The
formation of acidic compartments was quantified by flow cytometric analysis of acridine orange stained cells (10). Acridine
orange stains the cytoplasm green and the nucleus a dim red,
whereas acidic compartments fluoresce bright red. The intensity of the red fluorescence is proportional to the amount of
acidity. Following treatment, cells were stained with acridine
orange 1 µg/ml for 15 min at 37˚C. Bafilomycin A1 (5 nM) was
dissolved in DMSO and added to the cells 45 min prior to the
addition of acridine orange. Cells were then trypsinised and
collected in phenol-red free medium. Green (510-530 nm) and
red (650 nm) fluorescence emission from 104 cells illuminated

with blue (488 nm) excitation light was measured with a CyAn
ADP Flow Cytometry Analyzer (Beckman Coulter, Nyon,
Switzerland). The red:green fluorescence ratio for individual
cells was calculated using FlowJo software (Tree Star, Inc.,
San Carlos, CA).
In vivo studies. Tumour growth was initiated by subcutaneous
injection of a CT-26 cell suspension (106 cells) into the right
flank of 6-8 week old female Balb/c mice. The experiments
were conducted on Day 7 when tumours reached a maximum
diameter range of 3.6-6.3 mm. Mice were randomly divided
into two groups of five. The treatment group received a single
intraperitoneal (i.p.) injection of 40 mg/kg CAZ-3 dissolved in
ethanol:cremophore:PBS [10%:10%:80% (v/v)] and the control
group received one i.p. injection of vehicle only. Tumour
growth was measured every second day with a sterile vernier
callipers. The long (L) and short (S) axes were recorded and
tumour volume (V) was calculated using the following equation V = (S2xL)/2. Mice were culled by CO2 asphyxiation at the
experimental end point. Ethical approval was obtained from
the Research Ethical Approval Committee, Trinity College
Dublin. The study was performed under the license number:
B100/4275 granted by Department of Health and Children,
Hawkins House, Dublin 2, Ireland.
Results
The effects of CA-4 and selected combretazets on the viability
of colon cancer-derived cell lines. The synthetic combretazets
were designed and synthesised with a view to improve the
stability, therapeutic efficacy and aqueous solubility of the
parent compound CA-4, hence many in the series contained
a phenolic group, phosphate ester or an amino group (Fig. 1).
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Table I. Evaluation of CA-4 and selected combretazets in adenocarcinoma-derived colon cancer cells.

Compound
CA-4
CAZ-1
CAZ-2
CAZ-3
CAZ-4
CAZ-5
CAZ-6
CAZ-7
CAZ-2P
CAZ-3P
CAZ-4P

CT-26
-------------------------------------------------IC50 (nM)
RI
5.7
11.8
13.46
4.25
165.0
136.9
118.0
245.3
75.17
8.0
9.7

Caco-2
-------------------------------------------------IC50 (nM)
RI

1.0
-2.1
-2.4
+1.4
-28.9
-24.1
-20.7
-43.0
-13.2
-1.4
-1.7

41.2
236.0
113.6
15.3
28.3
ND
120.7
704.2
96.7
109.3
ND

1.0
-5.7
-2.8
+5.6
+1.5
ND
-2.9
-17.1
-2.4
-2.7
ND

HT-29
-----------------------------------------------------IC50 (nM)
RI
9020
1011
909
50
3510
30
70
260
440
119
4670

1.0
+8.1
+9 (11)
+180.0
+2.6
+300.0
+128.9
+34.7
+20.5
+7.6
+1.93

Cells were exposed to multiple concentrations of the indicated compound for 72 h. Cell viability was assessed using the Alamar Blue assay
and respective IC50 values were calculated. ND, not determined. RI, relative inhibition, compared to CA-4. The most active analogue, CAZ-3,
is highlighted in bold.

Table II. Calculation of intrinsic clearance values (CLint) for
CA-4 and CAZ-3 in human microsomes.

Table III. Suppression of tumour growth by CAZ-3.

Compound

Group

CA-4
CAZ-3

CLint (µl/min/mg protein)

t1/2 (min)

157.0±18.9
76.7±21.4

8.83
18.1

Compounds (3 µM) were incubated in the presence of NADPH
(1 mM) and human liver microsomes (0.5 mg/ml) and intrinsic
clearance values were calculated as described in Materials and
methods. Clearance values are expressed as (µl/min/mg) of microsomal protein. Values represent the mean ± SEM of at least triplicate
determinations.

All combretazets analysed were effective in the nanomolar
range in drug-sensitive CT-26 and Caco-2 cells and were more
potent than CA-4 in CA-4 refractory HT-29 cells (Table I).
Compound CAZ-2 is identical to CA-4 with the exception of
the azetidinone-ethylene bridge substitution and demonstrated
an 8‑fold increase in activity in HT-29 cells confirming a
functional advantage of the ethylene bridge-azetidinone substitution in overcoming combretastatin resistance. Compounds
containing a B-ring meta-hydroxy group (CAZ-1, CAZ-2
and CAZ-4) or a phosphate (CAZ-2P, CAZ-3P and CAZ-4P)
conjugate were the least active of the series in the combretastatin refractory HT-29 cells. Deletion (CAZ-5) or substitution
of the B-ring meta-hydroxy group with an amine conjugated
amino acid (CAZ-6 and CAZ-7) significantly increased
activity of the series with IC50 values in the nanomolar range
in combretastatin refractory HT-29 cells. However, CAZ-3
with a B-ring meta-hydroxy group was the exception to this
observation. CAZ-3 was more potent than CA-4 in all three
adenocarcinoma-derived cell lines tested. Hence, CAZ-3 was
selected for further biological analysis.

Control
CAZ-3
Single IP
40 mg/kg

Tumour volume
(Day 7)

Tumour volume
(Day 11)

37.08±8.326
42.45±11.45
NS

263.2±62.13
77.62±19.24
<0.05a

Mortality
0/5
1/5

BALB/c mice (n=10) were inoculated subcutaneously with 106 CT-26
cells. On Day 7 mice received a single i.p. injection of vehicle
(ethanol:cremophore:PBS; 10%:10%:80%) or 40 mg/kg CAZ-3.
Tumour growth was measured every second day using a sterile
vernier callipers. Values represent the mean ± SEM (Student's t‑test;
a
P<0.05; NS, not significant).

The effects of CA-4 and selected combretazets on the cell cycle
in CT-26 cells. CT-26 cells were selected for further analysis
given that all combretazets were effective in the nanomolar
range in this cell line. The effects of CA-4, CAZ-3 and its
corresponding prodrug CAZ-3P on the cell cycle and cell
death were assessed by flow cytometric analysis of propidium
iodide stained CT-26 cells. The percentage of cell death was
estimated by the quantification of the pre-G1 peak. As shown
in Fig. 2, all compounds tested produced an early G2M cell
cycle arrest at 8 h followed by a significant time-dependent
increase in cell death.
Induction of autophagy by CAZ-3. Our recent findings demonstrated that CA-4 and CAZ-2 (CA-432) induced autophagy in
adenocarcinoma-derived colon cells as confirmed by acridine
orange staining of vesicle formation, electron microscopy
and increased expression of LC3-II (10). Hence, the effect of
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Figure 2. CAZ-3 and its prodrug CAZ-3P induce G2M cell cycle arrest and cell death in a similar manner to CA-4 in murine CT-26 adenocarcinoma cells.
CT-26 cells were treated with vehicle [ethanol 0.2% (v/v)] or 50 nM of compound for the times indicated. Cells were then fixed, stained with PI and analysed
by flow cytometry. The percentage of cell death was determined by quantification of the sub-G1 peak. Values represent the mean ± SEM for three independent
experiments (Student's t‑test: *P<0.05, **P<0.01).

CAZ-3 on autophagic vesicle formation was evaluated by flow
cytometric analysis of acridine orange stained cells. Fig. 3
indicates that like other combretastatins CAZ-3 also induced
autophagy in adenocarcinoma cells. Furthermore, CAZ-3 also
induced autophagy in HT-29 and Caco-2 adenocarcinomaderived colon cancer cells (data not shown). Numerous studies
have demonstrated a dependence of the acidification of cellular
organelles on the vacuolar H+ ATPase using the specific inhi
bitor bafilomycin A1. Similarly, pretreatment of CT-26 cells
with bafilomycin A1 significantly inhibited CAZ-3 induced
autophagy (Fig. 3).
CAZ-3 is more stable than CA-4 in both human plasma and
microsomes. The stability of CA-4 and CAZ-3 in acidic media
and in human plasma was next determined by HPLC. Both
compounds were stable in plasma at physiological pH 7.3
for up to 5 h (Fig. 4A) and remained stable up to 24 h (data
not shown). Under acidic conditions (pH 3.0) CAZ-3 is more

stable than CA-4 (Fig. 4B). These findings are in agreement
with other studies demonstrating instability of CA-4 in acidic
media (12). Microsome stability was determined using pooled
human liver microsomes (Table II). The β -lactam bridge
improved the metabolic stability of CAZ-3 as compared with
CA-4 by doubling the in vitro clearance time.
CAZ-3 significantly inhibited the growth of CT-26 cells grafted
to mice. To study the effects of CAZ-3 on tumour growth we
selected the CT-26 murine model of colon carcinoma, a model
frequently used to test the efficacy of CA-4 and its synthetic
analogues (13). Furthermore, experimental models involving
xenografts of human tumours in a mouse host may lack some of
the critical tumour host interactions. In the antitumour efficacy
experiment mice received a single IP injection of 40 mg/kg
on Day 7 when tumours were on average 5 mm in diameter.
On Day 7 there was no significant difference between control
and CAZ-3 treated groups. By Days 9 (data not shown) and
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Figure 3. CAZ-3 induces autophagy in adenocarcinoma-derived cell lines. Cells were treated with ethanol vehicle [0.2% (v/v)] or 50 nM CAZ-3 ± BAF-A1
(5 nM). BAF-A1 was added 45 min before the addition of acridine orange. After 48 h, cells were stained with 1 µg/ml acridine orange for 15 min. The differential staining of acridine orange can detect the acidic vesicles of autophagic cells. (A) Representative flow cytometry dot plots are shown of acridine orange
stained CT-26 cells. The acidic vesicles of the autophagic cells (top left and right quadrants) were quantified by FlowJo software. (B) Values represent the
mean ± SEM for at least three independent experiments (Student's t-test: *P<0.05).

Figure 4. Analysis of the stability of CA-4 and CAZ-3 in plasma and at pH 3.0 over time. Compounds were incubated at 37˚C in plasma pH 7.3 (A) or PBS
pH 3.0 (B) and aliquots were taken and analysed by HPLC at various time intervals. The percentage recovery was calculated using the formula [(plasma or
pH 3.0 peak area/mean aqueous peak height) x 100]. The absence of an error bar indicates that the error was smaller than the size of the symbol. Results are
expressed as the mean ± SEM for three independent experiments (two-way ANOVA with Bonferroni post tests: **P<0.001).

11 (Table III), CAZ-3 significantly inhibited tumour growth.
Both a rough coat and diarrhoea were observed in 100% of
CAZ-3 treated mice.
Discussion
Several water soluble CA-4 analogues including CA-4P
(ZYBRESTAT), CA-1P (OXi4503) and AC7700 (AVE 8062)
are currently undergoing clinical trials as vascular targeting
agents (www.clinicaltrials.gov) (14,15). However, these
compounds all contain the isomerisable olefinic bond which
may hinder the continued clinical success of the compounds.
To date there is no cis-stable CA-4 analogue undergoing
clinical trials and hence there is a demand for pre-clinical data
on potent cis-restricted CA-4 analogues. The combretazets

are a novel class of synthetic combretastatin and azetidinone
(β-lactam) hybrids that function through a combretastatin-like
mechanism. Overall the combretastatins and the combretazets
are structurally and functionally similar. Both classes exhibit
a similar spatial arrangement between the two phenyl A and B
rings but differ in the bridge structure connecting the rings. The
strategic ethylene bridge-azetidinone substitution produced
cis-stable analogues with improved chemical stability and ease
of synthesis. Extensive biochemical analysis demonstrated that
the ethylene bridge-azetidinone substitution did not influence
the biological properties of CA-4 (9,10,16,17). In more detail,
both classes of drugs inhibit the polymerisation of tubulin
inducing a range of cellular responses including; G2M cell cycle
arrest, autophagy, mitotic catastrophe, caspase-dependent cell
death and caspase-independent cell death. In this report, we
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demonstrate that further substitutions to the aromatic ring at
position 3 of the azetidinone yielded a superior compound
with enhanced stability and potency against combretastatin
refactory adenocarcinoma-derived cells and tumours without
altering the biological properties of CA-4. The lead compound
CAZ-3 inhibited the polymerisation of tubulin (9), induced a
G2M cell cycle arrest and a time-dependent increase in cell
death (sub-G1) in the colon adenocarcinoma-derived CT-26
cells in a similar manner to its phosphate prodrug counterpart
(CAZ-3P) and CA-4. As recently observed with CA-4 (10),
CAZ-3 also induced autophagy in CT-26 adenocarcinoma
cells. Autophagy is a highly regulated self-catabolic process
which can facilitate a prolonged cell survival in spite of
adverse stress by generating energy via lysosomal degradation of cytoplasmic constituents (18). Furthermore, we have
previously demonstrated that manipulation of autophagy can
enhance the therapeutic potential of CAZ-2 (10).
The adenocarcinoma-derived HT-29 cells are inherently
resistant to CA-4. The mechanism of innate resistance remains
undefined. Recent studies rule out multidrug resistance
protein-1 (MRP-1) mediated resistance to CA-4 in HT-29
cells (12). MRP-1 is a member of the ATP-binding cassette
family of polytopic membrane transporters and is responsible
for conferring resistance to a broad range of chemotherapeutic drugs (19). However, the authors demonstrate a role
for MRP-1 in mediating resistance to some oxazole CA-4
derivatives (12). Data obtained from SARs from numerous
independent studies on CA-4 analogues provide some insight
into the possibility of structural modification of CA-4 as a
means of overcoming CA-4 resistance. In this report we
demonstrate that a substitution of the ethylene bridge with
a β -lactam ring (CAZ-1) increased activity in HT-29 cells
compared to CA-4 by 8‑fold. This finding would suggest that
cis-trans isomerisation is not solely responsible for CA-4
resistance in HT-29 cells but may contribute in part to CA-4
resistance in these cells. This mechanism of resistance may
be overcome by synthetic analogues featuring an ethylene
bridge substitution with various types of heterocyclic rings
yielding stable analogues which do not isomerise. We also
report that deletion or substitution of the B-ring meta-hydroxy
group with an amine conjugated amino acid in conjunction
with introduction of a 3-position aromatic ring significantly
enhances the activity of the series by up to 300‑fold in HT-29
cells as compared to CA-4. These findings are in agreement
with a recent report by Schobert et al (12) demonstrating
improved activity of oxazole bridged CA-4 analogues by
substitution of the B-ring phenolic group with H, fluoro or
amino groups. Also, substitution of the ethylene bridge with
a sulfone group coupled with the substitution of B-ring
with a 5-amino-6-methoxyquinoline moiety yielded a novel
compound with activity in the low nanomolar range in HT-29
cells (IC50 =16 nM) (20). Ring B 4-ethoxyphenyl 1,5-diaryl
substituted 1,2,3,4-tetrazoles also displayed potent activity
in HT-29 cells (21). Taken together these findings highlight
the potential of B-ring meta-hydroxy group substitutions
or deletions in cis-stable analogues of CA-4 as a means of
overcoming innate resistance to CA-4. However, our lead
compound CAZ-3, a cis-restricted CA-4 analogue with a
B-ring meta-hydroxy group demonstrated potent nanomolar
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activity in HT-29 cells. Molecular modelling studies highlighted a novel site of interaction between the para-phenolic
3-position of compound CAZ-3 with the colchicine binding
site of tubulin (9). This unique tubulin binding characteristic
is shared with compound CAZ-5 via the B-ring ethoxy group
but not with CA-4 and the other listed β -lactams (11). The
additional hydrophobic contact of CAZ-3 and CAZ-5 with
tubulin may facilitate the observed potent antiproliferative
effects observed in the CA-4 resistant HT-29 cells and offer a
novel means of overcoming CA-4 resistance.
Based on promising in vitro data we proceeded to evaluate
the therapeutic efficacy of CAZ-3 in the mouse CT-26 model
of colon adenocarcinoma. As a single agent CA-4 failed to
reduce the growth of CT-26 tumours in vivo (13). Here we
report that a single injection of CAZ-3 (40 mg/kg) significantly
inhibited the growth of CT-26 tumours in vivo. Furthermore,
CAZ-3 reduced the tumour levels to 34% of control untreated
tumour size. This value is below the T/C value of 42% which
is defined as the minimum level of activity required by the
National Cancer Institute criteria. However, despite an excellent tumour response rate, a single i.p. injection of CAZ-3 at
40 mg/kg gave adverse side effects such as rough coat, loss of
appetite and diarrhoea along with a mortality rate of 1/5. The
single maximum tolerated dose for CA-4P was 360 mg/m2 in
rats and 100 mg/m2 in dogs (22). Serious diarrhoea has been
reported elsewhere in animals given an i.p. injection of CA-4
at 100 mg/kg (23). CA-4P (100 mg/kg) had a mortality rate
of 25% in rats (http://arno.unimaas.nl/show.cgi?fid=7247).
In 90% of patients CA-4P is well tolerated at 52 mg/m2 (22).
Given that CAZ-3 is intrinsically more stable than CA-4 and
has a slower intrinsic clearance time, CAZ-3 may be more
active in vivo as well as in vitro and thus may require significantly lower dosing rates. Optimising the dosing schedule
and/or administration route may yield more favourable results.
In conclusion, we have presented preclinical data on a novel
series of cis-stable combretastatin analogues. We demonstrate
that our lead compound CAZ-3 is effective against CA-4 resistant colon cancer-derived cells in vitro and in vivo. Further
studies are warranted to characterise the metabolites of CAZ-3
and optimise dosing schedules with a view to improving the
therapeutic potential of this novel class of cis-stable vascular
targeting agents.
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